Skip to main content
Caplight Logo









Akara

Akara

Private
DublinHealthcare & Life Scienceshttps://akara.ai

Last Round

Early Funding

Nov 11, 2026

Total Funding Raised

$8.52M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Akara operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was an Early Funding round in November 2026.

Akara is a healthcare technology company that develops an AI-powered platform and autonomous robots to optimize hospital workflows and improve clinical efficiency.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Industrial Robotics, Health IoT, Facility Management

Business Model

B2B

Customer Profile

Hardware + Subscription, Subscription SaaS

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Akara Comparables

Compare Akara with similar companies based on industry and business-model similarity.

Akara comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shyld AI
86%
Loop Robots
82%
3C GROUPS A/S
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Akara Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingNov 11, 2026
SeedMar 11, 2024
GrantOct 14, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Eamonn Bourke

COO Co-Founder

Founding Team

Michael Cullinan

Chief Technology Officer, Director Of Mechatronics And Co-founder

Founding Team

Niamh Donnelly

Co-Founder Chief Robotics Officer

Founding Team

Conor McGinn

CEO

Executive Team

For institutional investors. Book with your work email.

Akara Investors

Notable investors and investment history

Akara investors
InvestorRounds
Atlantic Bridge CapitalEarly Funding
ACT Venture CapitalEarly Funding
Locke HealthEarly Funding
European Innovation Council FundGrant
TechstarsSeed
CommonkindEarly Funding
Enterprise IrelandEarly Funding, Grant
Book a demo to see all 8 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 11, 2026

    $5.5M raised, led by Locke Health.

  • Sep 3, 2026

    Grew 24% QoQ, from 29 to 36 employees.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • expands_offices_inNov 11, 2026

    Akara plans to use its latest funding to expand its operations and engineering teams in Ireland, where its technology is already deployed in hospitals, while accelerating hospital adoption and advancing its AI agents across more healthcare applications.

  • is_developingNov 11, 2026

    Akara, already deployed in U.S. ambulatory surgery centers and hospitals, plans to use funding to expand its operations and engineering teams, accelerate adoption, and develop AI agents for more healthcare applications.

  • is_developingNov 11, 2026

    On Nov 11th '26, Akara is developing AI for hospital operations that combines privacy-preserving sensors, robots and AI tools to reduce administrative work, coordinate services and help hospitals treat more patients.

  • receives_financingNov 11, 2026

    On Nov 11th '26, Akara receives $5.5M in funding in California to develop AI for hospital operations, bringing its total funding to $12.3 million.

  • expands_offices_toAug 25, 2026

    Akara announces plans on Aug 25th '26 to expand its healthcare market presence into the United States with robotics and artificial intelligence that automate hospital disinfection.

Book a demo to see all news

For institutional investors. Book with your work email.

Akara Filings

Explore SEC and related filing metadata, where available.

Akara filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Akara's valuation, stock price, and market status.

Is Akara a public or private company?

Akara is a private company.

What is the current stock price of Akara?

Akara is a private company, so its shares have no public market price. Caplight tracks Akara's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Akara worth (valuation)?

Valuation information for Akara is not publicly available.

Can I buy Akara stock?

Akara shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Akara's last funding round?

Akara's most recent funding round was Early Funding on November 11, 2026.

Who are the main investors in Akara?

Key investors in Akara include Locke Health, European Innovation Council Fund, Techstars.

Will Akara IPO soon?

No public IPO plans have been announced for Akara.

How can I track Akara secondary market activity?

Caplight tracks bids, offers, and trades in Akara's shares on secondary markets.

Firmographic Details

HeadquartersDublin
Employee Range16
Year Founded2019
Last FundingNov 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?